1. Home
  2. TKNO vs CRDL Comparison

TKNO vs CRDL Comparison

Compare TKNO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$2.01

Market Cap

107.1M

Sector

Health Care

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKNO
CRDL
Founded
1996
2017
Country
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.1M
97.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TKNO
CRDL
Price
$2.01
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
371.9K
332.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.64
N/A
Revenue Next Year
$9.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$0.77
52 Week High
$8.65
$1.59

Technical Indicators

Market Signals
Indicator
TKNO
CRDL
Relative Strength Index (RSI) 16.20 52.90
Support Level $1.96 $0.98
Resistance Level $2.26 $1.09
Average True Range (ATR) 0.28 0.06
MACD -0.01 0.00
Stochastic Oscillator 6.59 61.76

Price Performance

Historical Comparison
TKNO
CRDL

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: